title: Dabigatran (Pradaxa(®)): surgeon's friend or foe?
abstract: All clinicians, whether in primary or secondary care settings, are likely to encounter patients on this new anticoagulant. Therefore, it is imperative that clinicians are aware of the risks and benefits associated with dabigatran.
authors.affiliation: StR, Oral and Maxillofacial Unit Monkscourt Avenue, Airdrie, ML6 0JS.
authors.forename: N
authors.initials: N
authors.lastname: Syyed
authors.affiliation: Monklands Hospital, Monkscourt Avenue, Airdrie, ML6 0JS.
authors.forename: M
authors.initials: M
authors.lastname: Ansell
authors.affiliation: Southern General Hospital, Glasgow, G51 4TF.
authors.forename: V
authors.initials: V
authors.lastname: Sood
mesh_terms: D000991:Antithrombins / Q000494:pharmacology* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000069604:Dabigatran / Q000494:pharmacology* / Q000627:therapeutic use*; D003729:Dental Care; D006801:Humans; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000991:Antithrombins; D000069604:Dabigatran